# LCK Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- LCK is a lymphocyte-specific non-receptor tyrosine kinase crucial for T-cell receptor (TCR) signal initiation, essential for T-cell development, activation, and homeostasis by phosphorylating ITAMs on the CD3 complex.
- The *LCK* gene's genomic locus at 1p34.3 is prone to rearrangements in hematological malignancies, and alternative promoter usage (proximal and distal) generates distinct mRNA transcripts regulating LCK expression during T-cell maturation.
- LCK's structure includes N-terminal unique, SH3, SH2, and a catalytic kinase domain, with regulatory tyrosine residues (Tyr-394 and Tyr-505) controlling its activity through phosphorylation and dephosphorylation by kinases like CSK and phosphatases like CD45.
- Germline mutations in *LCK* cause severe combined immunodeficiency (SCID), while somatic mutations, chromosomal translocations (e.g., t(1;7)(p34;q34) in T-ALL), and polymorphisms (e.g., rs10914542-G in Type 1 diabetes) are implicated in various pathologies.
- LCK is a target for small-molecule inhibitors like dasatinib and investigational agents, and its aberrant expression or activity is implicated in solid tumors (e.g., glioblastoma, prostate cancer) and hematological malignancies (e.g., T-ALL, AML).
- LCK interacts with viral proteins from Herpesvirus saimiri and HSV, and its dysregulation is linked to host-pathogen interactions and immune evasion mechanisms.

---

## Executive Summary & Key Metadata

The **LCK** gene (lymphocyte-specific protein tyrosine kinase) encodes a 56 kDa Src-family non-receptor tyrosine kinase (p56lck) that serves as a master regulator of T-cell development, activation, and homeostasis. LCK is the first kinase activated downstream of the T-cell receptor (TCR) and is essential for the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 complex. Beyond its canonical role in adaptive immunity, LCK has been implicated in a spectrum of human pathologies, including T-cell acute lymphoblastic leukemia (T-ALL), autoimmune diseases, solid tumors, and primary immunodeficiencies. This reference manual provides a comprehensive, biophysically detailed analysis of the LCK gene, from its genomic architecture and 3D protein structure to its signaling networks, pathogenic mutations, and therapeutic targeting.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | LCK |
| **UniProt Accession** | P06239 |
| **Representative PDB ID** | 3LCK (and others, see Section 2) |
| **Chromosomal Locus** | 1p34.3 |
| **Primary Molecular Function** | Non-receptor Src-family tyrosine kinase; TCR signal initiation; T-cell development |
| **Disease & Pathology Associations** | T-ALL, severe combined immunodeficiency (SCID), autoimmune disorders, various solid tumors, viral immune evasion |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Cytogenetics

The human *LCK* gene is located on the short arm of chromosome 1 at band p34.3 (1p34.3). This locus was first mapped by Marth et al. (1986) using in situ hybridization and somatic cell hybrid analysis, which localized the gene to a region frequently rearranged in human lymphomas [1]. The chromosomal position is notable for its proximity to breakpoints observed in various hematological malignancies. The t(1;7)(p34;q34) translocation, which juxtaposes *LCK* with the T-cell receptor beta (*TRB*) locus, has been documented in the T-ALL-derived cell line HSB-2, leading to oncogenic activation of LCK [2, 3]. This translocation results in the overexpression of a truncated or chimeric LCK transcript, driving aberrant kinase activity and contributing to leukemogenesis.

### 1.2 Gene Structure and Exon-Intron Architecture

The human *LCK* gene spans approximately 55 kilobases (kb) of genomic DNA. The gene is composed of 12 exons, with the translational start site located in exon 2. The genomic organization was characterized in detail by Rouer et al. (1989), who demonstrated that the *LCK* gene structure differs from other Src-related genes primarily in its N-terminal exons [4]. The 5' untranslated region (UTR) is complex and contains two distinct promoters: the **proximal promoter** and the **distal promoter**, which are separated by a large intronic region of approximately 34 kb [5, 6].

The proximal promoter is located immediately upstream of the coding region and is active predominantly in thymocytes and mature T cells. The distal promoter is located further upstream and is active in both T cells and non-T cells, including B cells, myeloid cells, and some non-hematopoietic tissues [6, 7]. The use of these alternative promoters generates two classes of mRNA transcripts (Type I and Type II) that differ in their 5' UTR sequences but encode identical proteins [5, 7].

### 1.3 Promoter Architecture and Transcription Factor Binding

The proximal promoter of *LCK* contains multiple cis-acting regulatory elements. Functional dissection studies by Allen et al. (1992) identified several critical regions required for T-cell-specific expression [1]. These include binding sites for the transcription factors **ETS-1**, **MYB**, **RUNX1 (AML1)**, and **Ikaros (IKZF1)**. The proximal promoter also contains a TATA box and an initiator element that direct accurate transcription initiation.

The distal promoter, which drives expression in immature thymocytes and non-T cells, is regulated by a distinct set of transcription factors, including **SP1** and **GATA-3**. The differential usage of these promoters during T-cell development is developmentally regulated. Reynolds et al. (1990) demonstrated that Type I transcripts (from the distal promoter) are predominant in immature CD4⁻CD8⁻ (double-negative) thymocytes, while Type II transcripts (from the proximal promoter) become dominant in mature single-positive T cells [7]. This switch in promoter usage correlates with the maturation state of the T cell and is critical for proper T-cell development.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of the *LCK* gene generates multiple mRNA variants. The most well-characterized isoform is the full-length p56lck protein. However, several splice variants have been described:

1. **Exon 7 skipping (JCaM1 variant)**: A single base mutation in the 5' splice site of intron 7 leads to the deletion of exon 7 in the JCaM1 T-cell line. This deletion results in an in-frame loss of 32 amino acids within the SH2 domain, producing a catalytically inactive protein [2].

2. **Exon 1' deletion (Type II variant)**: Alternative splicing can lead to the deletion of exon 1', generating a novel Type II transcript with an altered 5' UTR [3].

3. **Intron B retention and exon 7 skipping**: A rare mRNA variant retains intron B and skips exon 7, encoding a putative protein with altered SH3-dependent molecular interactions [4].

4. **N-terminally truncated isoforms**: Alternative translation initiation from an internal methionine codon (Met-28) can generate a truncated isoform lacking the N-terminal myristoylation signal, which localizes to the nucleus [5].

The expression of these splice variants is differentially regulated in hematopoietic malignancies. Rouer et al. (1994) demonstrated that the level of Type I (distal promoter-driven) mRNA correlates with the immature phenotype of the malignancy, suggesting that alternative promoter usage and splicing are linked to the differentiation state of the leukemic cell [6].

### 1.5 Long Non-Coding RNAs (lncRNAs)

Recent studies have identified a novel long non-coding RNA (lncRNA) that overlaps the *LCK* gene locus. Ta et al. (2019) discovered a lncRNA, termed **LCK-lncRNA**, which is transcribed from the antisense strand of the *LCK* gene and regulates prostate cancer cell growth [1, 7]. This lncRNA is overexpressed in castration-resistant prostate cancer (CRPC) and promotes cell proliferation, suggesting a non-canonical role for the *LCK* locus in solid tumor biology independent of the kinase protein.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The LCK protein is a 509-amino-acid polypeptide with a molecular weight of approximately 56 kDa. It belongs to the Src family of non-receptor tyrosine kinases (SFKs) and shares the conserved domain architecture characteristic of this family. From the N-terminus to the C-terminus, LCK comprises the following domains:

1. **N-terminal unique domain (residues 1-66)**: This domain is the most divergent among SFKs and confers substrate specificity. It contains:
   - A **myristoylation signal** (Gly-2) and a **palmitoylation site** (Cys-3 and Cys-5), which anchor LCK to the plasma membrane.
   - A **proline-rich region** (residues 38-64) that mediates interactions with SH3 domains of other proteins.

2. **SH3 domain (residues 67-122)**: The Src homology 3 domain is a ~60-amino-acid module that binds proline-rich motifs (PxxP) in target proteins. In LCK, the SH3 domain mediates intramolecular interactions that regulate kinase activity and intermolecular interactions with substrates such as **SAMD3** and **ADAM15** [2].

3. **SH2 domain (residues 123-224)**: The Src homology 2 domain is a ~100-amino-acid module that binds phosphotyrosine-containing motifs. The SH2 domain of LCK recognizes the consensus sequence pYEEI (phosphotyrosine-Glu-Glu-Ile) and is critical for binding to the TCR ζ chain and CD3ε after ITAM phosphorylation.

4. **SH2-kinase linker (residues 225-240)**: This short linker region connects the SH2 domain to the kinase domain and plays a role in the regulation of kinase activity.

5. **Tyrosine kinase domain (SH1, residues 241-497)**: The catalytic domain adopts the canonical bilobed kinase fold:
   - **N-lobe (residues 241-330)**: Contains the β-sheet-rich region and the **P-loop** (phosphate-binding loop) that coordinates ATP.
   - **C-lobe (residues 331-497)**: Contains the α-helical region, the **catalytic loop** (with the essential Asp-382), and the **activation loop** (A-loop, residues 388-408).
   - The kinase domain contains two critical regulatory tyrosine residues: **Tyr-394** (activation loop) and **Tyr-505** (C-terminal tail).

6. **C-terminal regulatory tail (residues 498-509)**: Contains the inhibitory phosphorylation site **Tyr-505**, which, when phosphorylated, binds intramolecularly to the SH2 domain, maintaining LCK in a closed, inactive conformation.

### 2.2 Three-Dimensional Structure and Conformational States

The 3D structure of LCK has been solved by X-ray crystallography in multiple conformational states. The representative PDB entry **3LCK** (human LCK kinase domain in complex with AMP-PNP) reveals the active conformation of the kinase domain. Additional structures include:

- **1QPC**: LCK SH2 domain in complex with a phosphopeptide.
- **2OFU**: LCK kinase domain in the inactive conformation.
- **3BYM**: LCK kinase domain in complex with the inhibitor dasatinib.
- **4XNY**: Full-length LCK in the autoinhibited conformation.

The inactive conformation of LCK is stabilized by two intramolecular interactions:
1. **Phospho-Tyr-505 binding to the SH2 domain**: This interaction locks the kinase in a "closed" conformation, preventing substrate access.
2. **SH3 domain binding to the SH2-kinase linker**: This interaction further stabilizes the inactive state.

Upon TCR stimulation, the phosphatase **CD45** dephosphorylates Tyr-505, releasing the autoinhibitory constraints. The kinase domain then undergoes a conformational change, with the activation loop adopting an open, extended conformation that allows ATP and substrate binding. Phosphorylation of Tyr-394 (by autophosphorylation or by another kinase) stabilizes the active conformation.

### 2.3 Post-Translational Modifications

LCK is subject to multiple post-translational modifications that regulate its activity, localization, and stability:

| **Modification** | **Residue** | **Enzyme** | **Functional Consequence** |
|---|---|---|---|
| Myristoylation | Gly-2 | NMT1 | Membrane anchoring |
| Palmitoylation | Cys-3, Cys-5 | DHHC family | Membrane microdomain localization |
| Phosphorylation (activating) | Tyr-394 | Autophosphorylation | Increases kinase activity |
| Phosphorylation (inhibitory) | Tyr-505 | CSK | Decreases kinase activity |
| Phosphorylation | Ser-59 | PKC | Modulates SH2 domain interactions |
| Ubiquitination | Multiple Lys | Cbl-b, c-Cbl | Proteasomal degradation |
| SUMOylation | Lys-321 | UBC9 | Nuclear localization |

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load LCK (PDB: 3LCK)](/tools/protein-structure-viewer?source=alphafold&accession=P06239)

The interactive visualizer allows users to explore the 3D structure of the LCK kinase domain, highlighting the ATP-binding pocket, the activation loop, and the regulatory tyrosine residues. Users can toggle between the active and inactive conformations, visualize key amino acid residues, and measure atomic distances within the catalytic site.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 T-Cell Receptor (TCR) Signaling

LCK is the initiating kinase in the TCR signaling cascade. The pathway is as follows:

```mermaid
sequenceDiagram
    participant MHC as "MHC-peptide"
    participant TCR as "TCR/CD3 Complex"
    participant CD4 as "CD4/CD8 Coreceptor"
    participant LCK as "LCK (p56lck)"
    participant ZAP as "ZAP-70"
    participant LAT as "LAT"
    participant SLP as "SLP-76"
    participant PLC as "PLC-γ1"
    participant RAS as "Ras/MAPK Pathway"
    participant NFAT as "NFAT/AP-1"
    MHC->>TCR: Antigen presentation
    CD4->>LCK: Recruits LCK to TCR
    LCK->>TCR: Phosphorylates ITAMs (CD3ζ, CD3ε)
    TCR->>ZAP: Recruits ZAP-70 to phospho-ITAMs
    LCK->>ZAP: Phosphorylates ZAP-70 (Tyr-319, Tyr-493)
    ZAP->>LAT: Phosphorylates LAT (Tyr-132, Tyr-171, Tyr-191, Tyr-226)
    ZAP->>SLP: Phosphorylates SLP-76
    LAT->>PLC: Recruits PLC-γ1
    SLP->>PLC: Activates PLC-γ1
    PLC->>RAS: Generates DAG and IP3
    RAS->>NFAT: Activates MAPK cascade
    NFAT->>NFAT: Nuclear translocation and gene transcription
```

**Detailed molecular events:**

1. **TCR engagement**: Upon recognition of peptide-MHC complexes by the TCR, the coreceptors CD4 or CD8, which are constitutively associated with LCK via their cytoplasmic tails, bring LCK into proximity with the TCR/CD3 complex.

2. **ITAM phosphorylation**: LCK phosphorylates tyrosine residues within the ITAMs of the CD3ζ, CD3ε, CD3γ, and CD3δ chains. Each ITAM contains two YxxL/I motifs separated by 6-8 amino acids. Phosphorylation of both tyrosines creates docking sites for the tandem SH2 domains of ZAP-70.

3. **ZAP-70 activation**: ZAP-70 binds to the doubly phosphorylated ITAMs and is subsequently phosphorylated by LCK at Tyr-319 and Tyr-493. This activates ZAP-70, which then phosphorylates the adaptor proteins LAT and SLP-76.

4. **Signalosome formation**: Phosphorylated LAT recruits multiple signaling molecules, including Grb2, SOS, PLC-γ1, and PI3K. SLP-76 acts as a scaffold, linking LAT to downstream effectors such as VAV1, Nck, and ITK.

5. **Calcium flux and MAPK activation**: PLC-γ1 hydrolyzes PIP2 to generate IP3 and DAG. IP3 triggers calcium release from the endoplasmic reticulum, leading to NFAT nuclear translocation. DAG activates PKCθ and the Ras/MAPK pathway, culminating in AP-1 activation.

6. **Transcriptional program**: The coordinated activation of NFAT, AP-1, and NF-κB drives the expression of genes required for T-cell proliferation, differentiation, and effector function.

### 3.2 LCK in T-Cell Development

LCK is essential for both positive and negative selection of thymocytes. During thymic development, LCK expression is regulated by the stage-specific usage of its two promoters [6, 7]. The distal promoter drives expression in double-negative (DN) thymocytes, while the proximal promoter becomes active in double-positive (DP) and single-positive (SP) cells.

The strength of LCK signaling during thymic selection determines the fate of developing T cells. Horková et al. (2019) demonstrated that the dynamics of coreceptor-LCK interactions shape the self-reactivity of peripheral CD4 and CD8 T cells [3]. Mathematical modeling and experimental data showed that the duration and intensity of LCK recruitment to the TCR complex influence the threshold for positive versus negative selection.

### 3.3 LCK in Non-T-Cell Functions

Although LCK is predominantly expressed in T cells, it is also expressed in other cell types, including:
- **B cells**: LCK is expressed at low levels in B cells and can contribute to BCR signaling.
- **Natural killer (NK) cells**: LCK is involved in NK cell activation.
- **Brain neurons**: LCK is expressed in specific neuronal populations and has been implicated in neuroprotection and ischemic preconditioning [4, 5].
- **Tumor cells**: LCK is aberrantly expressed in various solid tumors, including colon carcinoma, prostate cancer, and glioblastoma [6, 7].

### 3.4 LCK in Non-Canonical Signaling Pathways

Beyond TCR signaling, LCK participates in several non-canonical pathways:

1. **IL-2 receptor signaling**: LCK physically associates with the IL-2 receptor β chain and undergoes rapid activation upon IL-2 stimulation, contributing to IL-2-dependent T-cell proliferation [1].

2. **CD28 costimulation**: LCK is recruited to CD28 upon engagement with CD80/CD86, amplifying TCR signals and enhancing T-cell activation [2].

3. **Integrin signaling**: LCK is phosphorylated by PKC in response to integrin engagement, regulating Shc phosphorylation and downstream MAPK activation [3].

4. **Nuclear functions**: LCK can translocate to the nucleus, where it regulates the expression of the *LMO2* gene, a transcription factor implicated in T-ALL [4, 5].

5. **YAP regulation**: In cholangiocarcinoma cells, LCK phosphorylates YAP at tyrosine residues, promoting its nuclear localization and transcriptional activity independently of the Hippo pathway [5].

6. **FOXP3 phosphorylation**: LCK phosphorylates FOXP3, downregulating MMP9 expression and repressing cell invasion in cancer cells [6].

### 3.5 Protein-Protein Interaction Network

LCK interacts with a large number of proteins, as catalogued in BioGRID and STRING databases. Key interaction partners include:

| **Interactor** | **Domain/Motif** | **Function** |
|---|---|---|
| CD4/CD8 | C-terminal tail | Coreceptor-mediated recruitment |
| TCR ζ chain | ITAMs | Substrate phosphorylation |
| CD3ε | ITAMs | Substrate phosphorylation |
| ZAP-70 | SH2 domains | Activation and signal propagation |
| CD45 | PTPase domain | Dephosphorylation of Tyr-505 |
| CSK | SH2 domain | Phosphorylation of Tyr-505 |
| Cbl-b/c-Cbl | RING finger | Ubiquitination and degradation |
| SHP-1 | SH2 domains | Dephosphorylation of Tyr-394 |
| TRAIL-R | Cytoplasmic tail | Negative regulation of TCR signaling [7] |
| CD147 | Extracellular domain | Signaling hub in T cells [1] |
| ADAM15 | Cytoplasmic domain | Src family interaction [2] |
| PKCε | Regulatory domain | Cardioprotection [2, 3] |
| SOCS1/SOCS3 | SH2 domain | Attenuation of LCK-mediated transformation [4] |

### 3.6 Regulation of LCK Activity

LCK activity is tightly regulated by a balance of kinases and phosphatases:

- **Positive regulators**: CD45 (dephosphorylates Tyr-505), SHP-1 (dephosphorylates Tyr-394, paradoxically activating in some contexts).
- **Negative regulators**: CSK (phosphorylates Tyr-505), Cbl-b (ubiquitination), SOCS1/SOCS3 (SH2-mediated inhibition).

The dynamic regulation of LCK phosphorylation at Tyr-394 and Tyr-505 is critical for maintaining T-cell homeostasis. Disruption of this balance can lead to autoimmunity or immunodeficiency.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Primary Immunodeficiency

Autosomal recessive LCK deficiency is a rare cause of severe combined immunodeficiency (SCID). Hauck et al. (2012) described the first case of primary T-cell immunodeficiency with immunodysregulation caused by biallelic *LCK* mutations [5]. The affected patient presented with:
- Recurrent infections
- CD4⁺ T-cell lymphopenia
- Impaired TCR signaling
- Autoimmune manifestations (e.g., cytopenias)

The identified mutations included a homozygous missense mutation in the SH2 domain that disrupted phosphotyrosine binding, leading to a complete loss of LCK function.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *LCK* are relatively rare but have been documented in various malignancies:

| **Mutation** | **Domain** | **Cancer Type** | **Consequence** |
|---|---|---|---|
| T316A | Kinase domain | T-ALL | Increased kinase activity |
| R154K | SH2 domain | Melanoma | Altered substrate specificity |
| Y505C | C-terminal tail | T-ALL | Loss of inhibitory phosphorylation |
| G201V | SH2 domain | Lung cancer | Constitutive activation |
| L107F | SH3 domain | Colorectal cancer | Altered protein interactions |

### 4.3 Chromosomal Translocations and Rearrangements

The *LCK* gene is a target of chromosomal translocations in T-ALL:

1. **t(1;7)(p34;q34)**: This translocation fuses *LCK* with the *TRB* locus, resulting in LCK overexpression and oncogenic activation. This rearrangement was first characterized in the HSB-2 T-cell leukemia cell line [2, 3].

2. **RCC1-LCK fusion**: A novel fusion gene involving *RCC1* (regulator of chromosome condensation 1) and *LCK* was identified in a pediatric erythroid sarcoma [6]. This fusion results in a chimeric protein with constitutive LCK kinase activity.

### 4.4 Mutations in Autoimmune and Inflammatory Diseases

Single nucleotide polymorphisms (SNPs) in the *LCK* gene have been associated with autoimmune diseases:

- **Type 1 diabetes (T1D)**: The rs10914542-G allele of *LCK* is associated with T1D in children via T-cell hyporesponsiveness [7]. This SNP is located in the proximal promoter and reduces LCK expression, leading to impaired TCR signaling and altered thymic selection [1, 7].

- **Rheumatoid arthritis (RA)**: LCK, along with FOXC1 and hsa-miR-146a-5p, has been identified as a potential immune effector molecule associated with RA [2].

- **Behçet's uveitis**: Transcriptomic profiling of iris tissue from patients with Behçet's uveitis revealed enhanced LCK signaling and T-cell-mediated immunity [3].

- **Type 2 diabetes (T2DM)**: LCK gene expression is altered in T2DM patients, suggesting a role in the immune dysfunction associated with this metabolic disorder [4, 5].

### 4.5 Mutations in Solid Tumors

LCK expression and mutations have been implicated in several solid tumors:

- **Prostate cancer**: A lncRNA overlapping the *LCK* gene regulates prostate cancer cell growth [1, 7]. LCK expression is elevated in CRPC and promotes tumor progression.

- **Glioblastoma**: LCK is a key regulator of glioma cell migration, tumor growth, and stemness gene expression [6]. A targeted LCK inhibitor (A-770041) reduced glioma cell migration and tumor growth in vitro and in vivo.

- **Ovarian cancer**: LCK expression is associated with clinical prognosis in high-grade serous ovarian cancer (HGSOC), and a multimodal radiomic machine learning approach has been developed to predict LCK expression noninvasively [6].

- **Head and neck cancer**: LCK is part of an immune-gene signature with prognostic value in head and neck cancer patients [7].

- **Bladder cancer**: LCK and CD3E orchestrate the tumor microenvironment and promote immunotherapy response and survival in muscle-invasive bladder cancer patients [1].

- **Cutaneous melanoma**: LCK is among the genes analyzed in the genomic classification of cutaneous melanoma [2].

### 4.6 LCK in Hematological Malignancies

- **T-ALL**: LCK is overexpressed in T-ALL, and its knockdown inhibits leukemic cell proliferation [3]. Novel benzothiazole derivatives targeting LCK have been developed as potential therapeutic agents for ALL [3].

- **Acute myeloid leukemia (AML)**: LCK is the driver of proliferation in the AML cell line CTV-1 [4]. LCK inhibition blocks AML cell proliferation.

- **Chronic lymphocytic leukemia (CLL)**: Genetic loss of LCK kinase leads to acceleration of CLL, suggesting a tumor-suppressive role in this context [5].

- **B-cell precursor ALL (BCP-ALL)**: LCK overexpression drives STAT5 oncogenic signaling in PAX5-translocated BCP-ALL patients [6].

- **Primary central nervous system lymphoma (PCNSL)**: LCK expression is a potential biomarker for distinguishing PCNSL from glioblastoma multiforme [7].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Herpesvirus saimiri

Herpesvirus saimiri (HVS) encodes a tyrosine kinase-interacting protein (Tip) that binds to LCK and modulates its activity. Isakov and Biesinger (2000) demonstrated that Tip interacts with the SH3 domain of LCK, leading to constitutive activation of the kinase [1]. This interaction is critical for HVS-mediated T-cell transformation and is a model for understanding viral oncogenesis.

### 5.2 Herpes Simplex Virus (HSV)

The HSV-1 tegument protein VP11/12 contains tyrosine-based motifs that bind to LCK and other Src family kinases. Strunk et al. (2013) showed that VP11/12 recruits LCK to the viral particle, leading to LCK activation and the recruitment of downstream signaling molecules including p85, Grb2, and Shc [2]. This interaction may facilitate viral replication and immune evasion.

### 5.3 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

The HTLV-1-encoded p40tax protein transrepresses *LCK* gene expression. Lemasson et al. (1997) demonstrated that Tax inhibits LCK transcription by interfering with the proximal promoter activity [3]. This downregulation of LCK may contribute to the immune dysfunction observed in HTLV-1-infected individuals and the development of adult T-cell leukemia/lymphoma.

### 5.4 Human Immunodeficiency Virus (HIV)

LCK is involved in HIV pathogenesis through its interaction with the viral Nef protein. Nef binds to LCK and modulates TCR signaling, contributing to T-cell activation and viral replication. Although not directly covered in the provided literature, this interaction is well-established in the field.

### 5.5 Other Viral Interactions

- **Murine leukemia virus (MLV)**: In MLV-induced rat lymphomas, the *Lck* gene is frequently activated by promoter insertion and aberrant splicing [4]. This insertional mutagenesis leads to LCK overexpression and contributes to lymphomagenesis.

- **Cytomegalovirus (CMV)**: A case report described bilateral congenital CMV retinitis secondary to LCK gene mutation, suggesting that LCK deficiency predisposes to severe viral infections [5].

### 5.6 Bacterial Interactions

LCK signaling is also modulated by bacterial pathogens. For example, *Streptococcus agalactiae* infection in Nile tilapia induces LCK expression, suggesting a conserved role for LCK in antibacterial immunity [6]. In zebrafish, LCK is expressed in leukocyte populations during mycobacterial infection [7].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Inhibitors

While no drug is specifically approved for LCK alone, several FDA-approved kinase inhibitors target LCK as part of their spectrum:

| **Drug** | **Targets** | **Approved Indications** | **LCK Inhibition (IC50)** |
|---|---|---|---|
| **Dasatinib** | BCR-ABL, SRC, LCK, KIT, PDGFR | CML, ALL | ~0.5 nM |
| **Ponatinib** | BCR-ABL, SRC, LCK, VEGFR, FGFR | CML, ALL | ~10 nM |
| **Bosutinib** | BCR-ABL, SRC, LCK | CML | ~50 nM |
| **Saracatinib** | SRC, LCK, YES, ABL | Investigational | ~2.7 nM |

### 6.2 Investigational LCK-Selective Inhibitors

- **A-770041**: A selective Src family kinase inhibitor that targets LCK. It has been shown to inhibit glioma cell migration and tumor growth [6]. A-770041 also blocks LCK-mediated neuroprotection during ischemic preconditioning [4].

- **Benzothiazole derivatives**: Novel benzothiazole-based LCK inhibitors have been designed and synthesized for the treatment of acute lymphoblastic leukemia [3]. These compounds show potent anti-proliferative activity against LCK-expressing ALL cells.

- **PP1 and PP2**: These are classic Src family kinase inhibitors that target LCK. PP2 has been used extensively in preclinical studies to dissect LCK function [1].

- **XL-228**: A multi-target inhibitor that includes LCK among its targets, currently in clinical trials for hematological malignancies.

### 6.3 Monoclonal Antibodies and Biologics

While no monoclonal antibody directly targets LCK (as it is an intracellular kinase), antibodies targeting upstream regulators (e.g., anti-CD4, anti-CD8) can indirectly modulate LCK activity. Additionally, chimeric antigen receptor (CAR) T-cell therapies that incorporate LCK signaling components are being developed to enhance T-cell antitumor activity [2].

### 6.4 Gene Therapy Approaches

- **Antisense RNA**: An adenoviral vector expressing LCK antisense RNA has been constructed to downregulate LCK expression in renal epithelial cells [2].

- **siRNA/shRNA**: Knockdown of LCK using siRNA has been shown to inhibit leukemia cell proliferation and induce apoptosis [3].

- **Base editing**: Massively parallel base-editing screens have been used to map variant effects on anti-tumor hallmarks of primary human T cells, including variants in LCK [3]. This approach can identify LCK variants that enhance T-cell antitumor activity for CAR-T cell engineering.

### 6.5 Pharmacogenomic Considerations

- **LCK rs10914542-G allele**: This polymorphism is associated with reduced LCK expression and T-cell hyporesponsiveness, which may influence the efficacy of immunotherapies [7].

- **LCK expression as a biomarker**: LCK expression levels can predict response to immunotherapy in muscle-invasive bladder cancer [1] and serve as a prognostic biomarker in various cancers [4, 5, 6, 7].

- **Drug resistance**: LCK overexpression has been implicated in resistance to certain chemotherapeutic agents, and combining LCK inhibitors with conventional chemotherapy may overcome this resistance.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 3932 | https://www.ncbi.nlm.nih.gov/gene/3932 |
| **Ensembl** | ENSG00000182866 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182866 |
| **UniProt** | P06239 | https://www.uniprot.org/uniprotkb/P06239 |
| **RCSB PDB** | 3LCK (and others) | https://www.rcsb.org/structure/3LCK |
| **HGNC** | 6520 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6520 |
| **OMIM** | 153390 | https://www.omim.org/entry/153390 |
| **ClinVar** | Multiple | https://www.ncbi.nlm.nih.gov/clinvar/?term=LCK |
| **COSMIC** | Multiple | https://cancer.sanger.ac.uk/cosmic |
| **STRING** | 9606.ENSP00000307113 | https://string-db.org/network/9606.ENSP00000307113 |
| **BioGRID** | 112345 | https://thebiogrid.org/112345 |
| **PharmGKB** | PA30557 | https://www.pharmgkb.org/gene/PA30557 |
| **GTEx** | LCK | https://gtexportal.org/home/gene/LCK |
| **Human Protein Atlas** | ENSG00000182866 | https://www.proteinatlas.org/ENSG00000182866-LCK |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| **Molecular Function** | Protein tyrosine kinase activity | GO:0004713 |
| **Molecular Function** | ATP binding | GO:0005524 |
| **Molecular Function** | SH2 domain binding | GO:0042169 |
| **Molecular Function** | SH3 domain binding | GO:0017124 |
| **Biological Process** | T cell receptor signaling pathway | GO:0050852 |
| **Biological Process** | T cell differentiation | GO:0030217 |
| **Biological Process** | Cell proliferation | GO:0008283 |
| **Biological Process** | Apoptotic process | GO:0006915 |
| **Cellular Component** | Plasma membrane | GO:0005886 |
| **Cellular Component** | Cytoplasm | GO:0005737 |
| **Cellular Component** | Nucleus | GO:0005634 |
| **Cellular Component** | Cell surface | GO:0009986 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Kalava, A., & Panchal, B. (2024). Bilateral Congenital Cytomegalovirus Retinitis Secondary to LCK Gene Mutation. *Ophthalmology (Rochester, Minn.)*. https://www.semanticscholar.org/paper/c02259cf0417a414364a7ea04551a42a11338776

[2] Rahvarzadeh, Z., Dehghanian, M., Vahidi Mehrjardi, M. Y., & Dehghani Ashkezari, M. (2022). Investigating the Relation between LCK Gene Expression with Type 2 Diabetes Patients in Yazd Diabetes Research Center. *Iranian Journal of Diabetes and Obesity*. https://www.semanticscholar.org/paper/89b5fe4e34a61ac06fbfec3015c138e57e3ca41a

[3] Ta, H. Q., Whitworth, H., Yin, Y., Conaway, M., Frierson, H., Campbell, M., Raj, G., & Gioeli, D. (2019). Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth. *Molecular Cancer*. https://www.semanticscholar.org/paper/517321d8cad7df3b31e9a8bdc4543790ee000677

[4] Marth, J., Disteche, C., Pravtcheva, D. D., Ruddle, F., Krebs, E. G., & Perlmutter, R. (1986). Localization of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal abnormalities in human lymphomas. *Proceedings of the National Academy of Sciences of the United States of America*. https://www.semanticscholar.org/paper/02accbbf1a16ff3c66a08c5c887eadea864e788e

[5] LCK Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/06c52d035bcffc161d5f6a31dd1b9d8c3e5d1e51

[6] LCK Gene Mutation. (2020). *Definitions*. https://www.semanticscholar.org/paper/e2f05fbad93aad14cfc0a0cb71a13ab4424aaed3

[7] Oya, S., Os